During the recent session, Royalty Pharma plc (NASDAQ:RPRX)’s traded shares were 1.87 million, with the beta value of the company hitting 0.48. At the last check today, the stock’s price was $33.08, reflecting an intraday gain of 1.02% or $0.33. The 52-week high for the RPRX share is $34.20, that puts it down -3.39 from that peak though still a striking 27.3% gain since the share price plummeted to a 52-week low of $24.05. The company’s market capitalization is $19.00B, and the average trade volume was 4.58 million shares over the past three months.
Royalty Pharma plc (RPRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. RPRX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 1.03.
Royalty Pharma plc (NASDAQ:RPRX) trade information
Royalty Pharma plc (RPRX) registered a 1.02% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.02% in intraday trading to $33.08, hitting a weekly high. The stock’s 5-day price performance is 1.86%, and it has moved by 7.24% in 30 days. Based on these gigs, the overall price performance for the year is 16.13%.
The consensus price target of analysts on Wall Street is $51, which implies an increase of 35.14% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $28 and $51 respectively. As a result, RPRX is trading at a discount of -54.17% off the target high and 15.36% off the low.
Royalty Pharma plc (RPRX) estimates and forecasts
In the rating firms’ projections, revenue will increase 24.58% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 657.8M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 718.61M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 537M and 565M respectively. In this case, analysts expect current quarter sales to grow by 22.50% and then jump by 27.19% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -21.51%. While earnings are projected to return 8.72% in 2025, the next five years will return 11.50% per annum.
RPRX Dividends
Royalty Pharma plc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Royalty Pharma plc is 0.85, with the dividend yield indicating at 2.57 percent, continuing the trend of increasing dividends in recent years.
The next largest institutional holding, with 38.02 million shares, is of VANGUARD GROUP INC’s that is approximately 8.4303% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.0 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Royalty Pharma plc (RPRX) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 11.74 shares. This amounts to just over 2.71 percent of the company’s overall shares, with a $392.51 million market value. The same data shows that the other fund manager holds slightly less at 8.12, or about 1.87% of the stock, which is worth about $271.44 million.
